Skip to main content

Table 1 Baseline demographic, clinical and immunological features of the study population

From: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study

Male/female 9 (30%)/21 (70%)
Age (years) 51 (41.75 to 62)
Disease duration (years) 3 (1 to 6)
Anti-DNA topoisomerase I/anti-centromere antibodies 28 (93.3%)/1 (3.3%)
Systemic sclerosis, lcSSc/dcSSc 14 (46%)/16 (53.3%)
Pulmonary function tests  
 FVC% predicted 76.5 (63.23 to 89.30)
 TLC% predicted 75 (65 to 86)
 DLco% predicted 43 (37 to 54)
High-resolution computed tomography  
 Ground-glass 10 (6 to 13.75)
 Honeycombing 10.5 (6.25 to 16.25)
Modified Rodnan skin score 10.5 (5.25 to 20)
Health Assessment Questionnaire 0.375 (0 to 1)
  1. Data presented as number of patients (%) or median (25th to 75th percentile). dcSSc, diffuse cutaneous systemic sclerosis; DLco, diffusion lung capacity of carbon monoxide; FVC, forced vital capacity; lcSSc, limited cutaneous systemic sclerosis; TLC, total lung capacity.